Cardiocast

Forget what you learned about infective endocarditis

Publish date: March 7, 2019

 

This week in MDedge Cardiocast: Infective endocarditis isn’t what it used to be, there’s a new, lower goal for Americans’ dietary intake of sodium, a drug to treat multiple myeloma also raises heart failure risk, and Big Pharma says it can’t drop drug list prices alone.
Amazon Alexa
Apple Podcasts
Google Podcasts
TuneIn

Recommended Reading

New diabetes drugs solidify their cardiovascular and renal benefits
MDedge Family Medicine
SGLT-2 inhibitors promising for heart failure prevention, not treatment
MDedge Family Medicine
HDL-P subfractions may be prognostic in heart failure
MDedge Family Medicine
Subclinical hypothyroidism boosts immediate risk of heart failure
MDedge Family Medicine
Atrial fib guidelines updated, SPRINT MIND published, and more
MDedge Family Medicine
Immunotherapy’s cardiac effects require early monitoring, management
MDedge Family Medicine
Therapy ups breast cancer survivors’ cardiac risks
MDedge Family Medicine
SGLT2 inhibitors morph into HF drugs
MDedge Family Medicine
What comes first with SGLT2 inhibitors – diabetes or heart failure?
MDedge Family Medicine
Infective endocarditis isn’t what it used to be
MDedge Family Medicine